Adare Expands High Potency Handling Capabilities in US and Europe
The CDMO plans to expand and upgrade its Philadelphia, Ohio, and Milan facilities to meet the continued growth in demand for high potency handling capabilities.
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com
Adare Pharma Solutions, a global contract development and manufacturing organization (CDMO) focused on oral dosage forms, has announced plans to expand its high potency handling capabilities in the United States and Europe. This expansion will include a second high potency suite to Adare’s facility in Philadelphia, upgrades to R&D suites in its Ohio facility, and high potency upgrades to its facility in Milan, Italy.
Adare’s 128,000 sq ft Orthodox Street facility in Philadelphia will receive a second high potency suite, which will add encapsulation, blending, high-shear granulation, and other manufacturing processes. These processes will bolster the site’s existing potent suite, which provides bin blending, roller compaction, milling, and tablet compression. Construction is set to complete by Q4 of 2024.
Work has already begun on the company’s 179,000 sq ft Vandalia facility in Ohio and is also scheduled to complete by Q4 of 2024. The Ohio facility is receiving upgrades to several of its R&D-to-clinical stage production suites to provide high potency handling. Capabilities will include microencapsulation, dry roller compaction, and fluid bed processing.
The expansion to Adare’s 220,000 sq ft Pessano facility in Milan, Italy will add high potency upgrades to its formulation and analytical laboratories, which include bin blending, fluid bed processing, compression, encapsulation, and pan-coating capabilities. Additionally, the facility recently announced plans to add packaging capabilities and more warehouse capacity (2). A two-story, 2800 square-meter extension is underway to accommodate a new packaging line in a specially built packaging hall, which is projected to be installed by Q4 2024. The expansion also contains a 1000 square-meter warehouse with capacity for 900 pallets and space for a second future packaging line.
A week after its packaging and warehouse expansions were announced, Adare revealed further expansions to the Milan site, adding a high-shear mixer granulator to its existing fluid bed capabilities (3). The granulator, an IMA 600-L Roto Mix high-shear mixer with IMILL and Hydrowash, provides wet granulation with either aqueous or organic-based solutions. The mixer’s design allows for lower changeover times and lower water and energy consumption as compared to traditional machine clean-down routines. These expansions, as well as the high potency upgrades, are expected to be operational by the end of 2024.
“We have seen demand for high potency handling and packaging continue to increase, with around half of solid dose drugs in development being highly potent,” said Tom Sellig, CEO of Adare Pharma Solutions, in a company press release (1). “This proactive investment across our global network of sites will ensure we continue to provide customers with the oral dose capabilities and capacity they will need both now and in the future.”
References
- Adare Pharma Solutions, Adare Expands Global High Potency Handling and Packaging Capabilities. Press Release, May 1, 2024.
- Adare Pharma Solutions, Adare Pharma Solutions to Expand Packaging and Warehousing Capabilities in Europe. Press release,Mar 5, 2024.
- Adare Pharma Solutions, Adare Pharma Solutions Expanding Oral Dose Capabilities in Europe. Press Release, Mar 12, 2024.
Source: Adare Pharma Solutions
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
